| INTRODUCTION
Equine protozoal myeloencephalitis (EPM) is a common and costly neurologic disease of horses in the United States. Despite a high seroprevalence nationally (>50%), it is unclear why only a small percentage (0.5%-1%) of horses develop clinical disease. Performance and shipping have been shown to be risk factors for EPM. 1 Other studies have demonstrated that some EPM-affected horses have decreased immune responses, including decreased antigen-specific proliferation, as well as increased interleukin-4 (IL-4) and decreased interferon-gamma (IFN-γ) expression, supporting a cluster of differentiation 4 (CD4) T helper 2 (Th2) response. [2] [3] [4] [5] [6] [7] Additional studies in mice in have supported a role for CD4 Th1 CD8 IFN-γ in protection because immunocompetent mice develop CD4 and CD8 memory responses, whereas IFN-γ knockout (KO) and CD8 KO mice develop
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disease. [8] [9] [10] Therefore, if efficacious immunomodulators could be found, they could be used as supplemental treatments for EPM.
Previously, levamisole has been proposed as an immunomodulatory treatment for EPM. 11 Levmamisole is an imidothiazole derivative with several actions that include antihelminthic, anti-inflammatory, antioxidant, antineoplastic, and immunomodulatory effects. 12 Experimental studies have demonstrated that levamisole can upregulate or downregulate, tolerize, or have no detectable effect on the immune response. 13, 14 Some of the variables in levamisole function appear to be related to the immune competence or phenotype of the individual animal and levamisole storage conditions (eg, temperature, pH, and concentration). Levamisole breaks down into 3 different metabolites (Table 1) . 15 Metabolite 1 after storage at 37 C or freshly prepared limits proliferation. Levamisole stored at 4 C generates metabolite 2, which is stimulatory. Metabolite 3 is generated from storage at 37 C but did not affect lymphocyte function. Levamisole administered to pregnant mares increased immunoglobulin G3 (IgG3) concentration in colostrum. 17 Additionally, neutrophils from the foals of treated mares had enhanced phagocytic activity.
Few additional studies have explored levamisole's effects on the equine immune response. Our goal was to evaluate the immunomodulatory effects of levamisole on the equine immune response and determine its potential use as a supplementary treatment for EPM. The predicted protective immune response against Sarcocystis neurona is a cellmediated immune response. Because proliferation of cells involved in cell-mediated immunity is 1 of the best methods of assessing immune function, our first objective was to define optimal in vitro conditions for detecting an effect of levamisole on the mitogenic response of stimulated equine peripheral mononuclear cells (PBMCs). Based on previous studies, 14, 15 we predicted that levamisole alone may have a minimal effect on the ability of cells to respond in vitro. We predicted levamisole would need to be combined with a mitogen to determine how levamisole affects proliferation of equine PBMCs. Therefore, to identify the predicted maximal response, we measured the change in levamisole effect with a mitogen to the effect of levamisole alone. We predicted the combination of levamisole with a mitogen would lead to the largest change in proliferation, which is a critical measure of immune function as opposed to activation only of cells. This system then was used to examine changes in PBMC phenotype associated with levamisole co-culture.
| MATERIAL AND METHODS
Equine PBMCs were isolated from 10 healthy neurologically normal adult horses and used to identify the optimal (ie, conditions that stimulated the largest change in proliferation between levamisole alone versus levamisole with a mitogen) conditions for levamisole in vitro based on cell proliferation. We predicted that this approach would allow us to identify the greatest potential for levamisole to affect the immune response. Equine PBMCs then were cultured using optimized conditions of levamisole to identify the immune phenotype based on proliferation of specific subsets of cells and cytokine production using flow cytometry and ELISAs. This study was approved by Institutional Animal Care and Use Committee (VT14-097).
| Horses
Peripheral blood mononuclear cells were isolated from 10 adult horses ranging in age from 2 to 24 years. Horse breeds included 4 Arabians, 2 Warmbloods, 2 Standardbreds, 1 Thoroughbred, and 1 Quarter horse. There were 7 geldings and 3 mares. Horses were determined to be healthy based on normal physical and neurologic examination findings. Horses were current on vaccinations and Coggins status, and had not been vaccinated within 2 weeks of the study. They were negative for Sarcocystis neurona based on a negative serum surface antigen 1, 5, 6 peptide ELISA (Pathogenes, Inc.).
| Collection of PBMCs
Blood samples were aseptically collected into lithium heparinized tubes by jugular venipuncture from each horse. 18 Peripheral blood mononuclear cells were isolated as previously described. 5 μg/mL; Sigma; positive control); fresh levamisole (Sigma; 1 μg/mL); fresh levamisole (10 μg/mL); levamisole 4 C (1 μg/mL); levamisole 4 C (10 μg/mL); levamisole fresh (1 μg/mL) and conA (5 μg/mL); levamisole fresh (10 μg/mL) and conA (5 μg/mL); levamisole 4 C
(1 μg/mL) and conA (5 μg/mL); levamisole 4 C (10 μg/mL) and conA (5 μg/mL). All the same treatments were also used with phorbol myristate acetate (20 μg/mL) and ionomycin (10 pg/mL; PMA/I) with and without levamisole. 18 Fresh levamisole was prepared immediately before use, whereas levamisole 4 C was stored 2 weeks before at 4 C, pH 7.5 before (levamisole 4 C) 15, 16 to replicate conditions for different levamisole metabolites. Levamisole prepared immediately before use was predicted to generate levamisole metabolite 1. Levamisole stored at 4 C for 2 weeks as described previously was predicted to generate levamisole metabolite 2 ( Table 1) . 15 Cells were stimulated for 72 hours. These studies were performed sequentially, and new preparations of levamisole were made for each study.
| Determination of proliferation using bromodeoxyuridine assay
After Plates were incubated at RT to allow color development. Plates were read at 370 nm with a reference wavelength of 492 nm. Both proliferation as well as change in proliferation between levamisole and a mitogen were determined.
| Experimental overview and treatment conditions for study 2
The PBMCs were isolated as described for study 1. Cell Trace was added to the cells from each horse before stimulation. Optimal conditions identified from study 1 indicated that fresh levamisole at 1 μg/mL with conA significantly decreased PBMC proliferation as compared to conA stimulation alone. Therefore, treatment conditions that were identified to determine how levamisole altered the immune phenotype were 5 μg/mL conA and 1 μg/mL fresh levamisole. For comparison, cells were cultured in media only (unstimulated), conA (5 μg/mL)
only, and levamisole (1 μg/mL made fresh) only. Cells were stimulated for 72 hours before harvesting for flow cytometry. 
| Proliferation based on CellTrace Violet staining

| Flow cytometric analysis using the FACS Aria
The percentages of each cell subset (CD4, CD8, CD21, CD14, and 3 | RESULTS the following treatment conditions were used: No mitogen, FL1 = 1 μg/mL levamisole freshly made, FL10 = 10 μg/mL levamisole freshly made, 4 L1 = 1 μg/mL levamisole stored at 4 C for 2 weeks, 4 L10 = 10 μg/mL levamisole stored at 4 C for 2 weeks, conA = Concanavalin A 5 μg/mL alone, CFL1 = conA and 1 μg/mL levamisole freshly made, CFL10 = conA and 10 μg/mL levamisole freshly made, C4L1 = conA and 1 μg/mL levamisole stored at 4 C for 2 weeks, C4L10 = conA and 10 μg/mL levamisole stored at 4 C for 2 weeks, PMAI = Phorbol myristate acetate 20 μg/mL and ionomycin 10 pg/mL (PMA/I), PFL1 = PMA/I and 1 μg/mL levamisole freshly made, PFL10 = PMA/I and 10 μg/mL levamisole freshly made, P4L1 = PMA/I and 1 μg/mL levamisole stored at 4 C for 2 weeks, P4L10 = PMA/I and 10 μg/mL levamisole stored at 4 C for 2 weeks. After 48 hours of stimulation, 20 μL of BrdU solution (Roche Life Sciences 11647229001) was added to each well. After 12 hours of incubation (72 hours total for cells), plates were harvested and proliferation was determined (Roche Life Sciences 11647229001). Change in proliferation between a mitogen with levamisole minus levamisole alone were determined. Statistically significant differences compared to unstimulated cells are marked with a star, P < .05. The error bars represent SD.
| Brdu proliferation assay
3.4 | Immune phenotype based on cell supernatant cytokine production by multiplex or ELISA
The concentrations of IFN-α, IL-4, IFN-γ, IL-17, and IL-10, all were significantly increased by the addition of conA or conA with levamisole as compared to unstimulated cells. However, there were no significant differences between conA and conA with levamisole. No significant differences were observed for IL-6 (Table 3) .
| Determination of proliferation using CellTrace
Although we followed the protocol for Cell Trace and optimized it for our laboratory, after additional review of our data, we determined that
CellTrace induced some degree of toxicity in our cells. Because we believe this toxicity impacted our proliferation results as detected by CellTrace, these data are not presented. Although the CellTrace may have influenced our remaining data, the results still are significant and valid under the conditions reported.
| DISCUSSION
Our data from study 1 supports that fresh levamisole at 1 μg/mL with conA induced a significant decrease in proliferation compared to conA only. Therefore, these conditions were used for study 2 to Our initial results from study 1 were unanticipated. We predicted that levamisole with a mitogen would increase proliferation, likely because of the formation of levamisole product 2. Concanavalin A or PMA/I with levamisole at 10 μg/mL significantly ( Figure 1 ) increased proliferation as compared to cells alone. However, when we calculated the change in proliferation between mitogen with levamisole minus mitogen alone, the conA with freshly made levamisole at 1 μg/mL significantly inhibited PBMC proliferation. Although we predicted, based on decreased proliferation that levamisole product 1 was present and had decreased proliferation, limited resources prevented identification of the levamisole metabolites present. In future studies, the levamisole products should be determined.
Our results also were unexpected that levamisole with conA did If levamisole product 1 is present, this potentially could decrease CD4 and CD8 cytokine production. Future studies should determine whether levamisole differentially activates macrophage and DC as compared to CD4 and CD8 cells.
In conclusion, we determined that conA with fresh levamisole at 1 μg/mL significantly decreased conA-induced proliferation. Levami- However, the possible effect of levamisole on immune preparedness (ie, the rate at which specific subsets of stimulated lymphocytes undergo phenotypic differentiation and initiate cytokine production) was not evaluated in our study. Additonal studies are warranted to elucidate these mechanisms.
